Engineered immune cells take on Hard-to-Treat brain cancer
NCT ID NCT07555561
First seen May 03, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This early-stage study is testing a new treatment for people with a rare and aggressive type of brain lymphoma that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells in the brain. The main goals are to check if the treatment is safe and to see if it can shrink tumors or stop them from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
RECRUITINGBeijing, Fengtai District, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.